159 related articles for article (PubMed ID: 31624377)
1. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.
Roex MCJ; van Balen P; Germeroth L; Hageman L; van Egmond E; Veld SAJ; Hoogstraten C; van Liempt E; Zwaginga JJ; de Wreede LC; Meij P; Vossen ACTM; Danhof S; Einsele H; Schaafsma MR; Veelken H; Halkes CJM; Jedema I; Falkenburg JHF
Leukemia; 2020 Mar; 34(3):831-844. PubMed ID: 31624377
[TBL] [Abstract][Full Text] [Related]
2. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
4. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH
Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation.
Gratama JW; Cornelissen JJ
BioDrugs; 2003; 17(5):325-38. PubMed ID: 14498763
[TBL] [Abstract][Full Text] [Related]
6. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
7. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blyth E; Clancy L; Simms R; Ma CK; Burgess J; Deo S; Byth K; Dubosq MC; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood; 2013 May; 121(18):3745-58. PubMed ID: 23435462
[TBL] [Abstract][Full Text] [Related]
8. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
9. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
10. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
Leen AM; Bollard CM; Mendizabal AM; Shpall EJ; Szabolcs P; Antin JH; Kapoor N; Pai SY; Rowley SD; Kebriaei P; Dey BR; Grilley BJ; Gee AP; Brenner MK; Rooney CM; Heslop HE
Blood; 2013 Jun; 121(26):5113-23. PubMed ID: 23610374
[TBL] [Abstract][Full Text] [Related]
11. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
12. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
van der Heiden PLJ; van Egmond HM; Veld SAJ; van de Meent M; Eefting M; de Wreede LC; Halkes CJM; Falkenburg JHF; Marijt WAF; Jedema I
Transpl Immunol; 2018 Aug; 49():54-58. PubMed ID: 29679650
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation.
Ip W; Silva JMF; Gaspar H; Mitra A; Patel S; Rao K; Chiesa R; Amrolia P; Gilmour K; Ahsan G; Slatter M; Gennery AR; Wynn RF; Veys P; Qasim W
Cytotherapy; 2018 Jun; 20(6):830-838. PubMed ID: 29753677
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
15. High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.
Pietersma FL; van Dorp S; Jacobi R; Ran L; Nanlohy NM; Schuurman R; Minnema MC; Meijer E; van Baarle D
Clin Infect Dis; 2010 Mar; 50(5):717-25. PubMed ID: 20121571
[TBL] [Abstract][Full Text] [Related]
16. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
[TBL] [Abstract][Full Text] [Related]
17. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
Fuchs KJ; van de Meent M; Honders MW; Khatri I; Kester MGD; Koster EAS; Koutsoumpli G; de Ru AH; van Bergen CAM; van Veelen PA; 't Hoen PAC; van Balen P; van den Akker EB; Veelken JH; Halkes CJM; Falkenburg JHF; Griffioen M
Blood; 2024 May; 143(18):1856-1872. PubMed ID: 38427583
[TBL] [Abstract][Full Text] [Related]
18. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Gerbitz A; Gary R; Aigner M; Moosmann A; Kremer A; Schmid C; Hirschbuehl K; Wagner E; Hauptrock B; Teschner D; Roesler W; Spriewald B; Tischer J; Moi S; Balzer H; Schaffer S; Bausenwein J; Wagner A; Schmidt F; Brestrich J; Ullrich B; Maas S; Herold S; Strobel J; Zimmermann R; Weisbach V; Hansmann L; Lammoglia-Cobo F; Remberger M; Stelljes M; Ayuk F; Zeiser R; Mackensen A
Front Immunol; 2023; 14():1251593. PubMed ID: 37965339
[TBL] [Abstract][Full Text] [Related]
19. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
20. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
Zilberberg J; Feinman R; Korngold R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
